JCJC - Jeunes chercheuses et jeunes chercheurs

Biodisponibilité de médicaments dans les boues biologiques : cas des anticancéreux et molécules associées – BioMedBoue

Submission summary

Anticancer drugs are frequently detected in aquatic environments at levels from 0.1 and 5 µg/l. These compounds are released after excretion from the patient and reached sewage systems via hospital or domestic wastewater. Most of these compounds are not completely removed during their passage through a conventional sewage treatment plants that were not designed to deal with these emerging pollutants. However, antineoplastics belong to the CMR (carcinogenic, mutanogenic or reprotoxic), they are often genotoxic and are assumed to be persistent in the aquatic environment because of their poor biodegradation. Then, several processes have been studied to improve elimination of these anti-tumour agents from effluents. Among them, biological treatment with membrane bioreactors can remove large amount of these pollutants from the aqueous phase (up to 70%, ANR Project ToxeauBam 2006-2009). But knowledge on mechanisms of their elimination (biodegradation or adsorption onto sludge) is still lacking. However sorption onto sludge could decrease bioavailability of these pollutants and could represent an important route for the pollutants into the environment when the sludge is used as fertilizer on agricultural land. So the understood of the mechanisms relevant for the removal of anticancer drugs is crucial for improving removal processes and for understanding the fate and impact of theses compounds in the environment. This purpose directly concerns the protection of water resources recommended by the European Water Framework Directive DCE 2000/60/CE and the French 'Grenelle' of the Environment. This project BioMedBoue aims at characterizing the bioavailability of anticancer drugs by measuring sorption partition coefficients on sludge and biodegradation kinetics constants. One of the original points of this study is to determine sorption coefficients not only on sludge particles but also on colloidal part which could also adsorb these compounds although this is still never taken into account in the literature. Thus, 5 anticancer drugs and metabolites will be studied (cyclophosphamide and two of its metabolites phosphoramid mustard and nor-nitrogen mustard; 5-fluorouracil and tamoxifen). The main steps of BioMedBoue project will be: ' Development of extraction and quantification methods for trace amounts of anticancer drugs in the different fractions of sludge (particulate, colloidal and aqueous). ' Characterisation of physical and chemical properties of sludge and their fractions ' Determination of sorption partition coefficients of these anti-tumour agents on the particulate and colloidal parts of different sludge (different retention time, acclimation or not with pollutant, classical activated sludge or sludge from membrane bioreactors,') in order to highlight parameters that could explain the sorption properties ' Determination of kinetics constants for biodegradation of the compounds for the same sludge as above ' Construction of a mathematical model able to predict sorption characteristics in relation with physical and chemical properties of sludge. ' Construction of a mathematical model able to predict anticancer drugs elimination and distribution in biological processes by coupling sorption equilibrium and biodegradation kinetics. ' Establishment of a methodology for the determination of impact factors of anticancer drugs in the environment in relation with their bioavailability.

Project coordinator

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.


Help of the ANR 0 euros
Beginning and duration of the scientific project: - 0 Months

Useful links

Explorez notre base de projets financés



ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter